Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.
Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.
Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.
Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.
et al., 2021, The diagnostic and prognostic significance of liver histology in alcoholic hepatitis, Alimentary Pharmacology and Therapeutics, Vol:53, ISSN:0269-2813, Pages:426-431
et al., 2021, NAFLD: time to apply quantitation in liver biopsies as endpoints in clinical trials, Journal of Hepatology, Vol:74, ISSN:0168-8278, Pages:241-242
et al., 2020, The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups, International Journal of Epidemiology, ISSN:0300-5771
et al., 2020, PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury, Journal of Clinical Investigation, ISSN:0021-9738
et al., 2020, O105. Faecal microbiota transplant (FMT) can reduce the high NRM associated with multi-drug resistant organism (MDRO) colonisation prior to allogeneic HCT., The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, Springer Nature [academic journals on nature.com], Pages:122-122, ISSN:0268-3369